UK 22:43 Wednesday, 30 September 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
I should declare that I am a shareholder in this company. I bought 1 share a few years ago so that I could attend its AGM to quiz the management on the catalogue of lies they had told to investors. Then covid struck. On a properly regulated market Advanced Oncotherapy (AVO) would have been given the order of the boot years ago, but this is AIM.
Does Advanced Oncotherapy (AVO) think that its shareholders are stupid as today’s RNS announcing yet another issuance of confetti ( 2.2 million shares to raise £550,691 gross) is quite obviously a load of cobblers.
AIM-listed Advanced Oncotherapy (AVO) has announced that Odey Asset Management is coughing up another £4.5 million as part of a £6 million fundraise to add to its investment in March of £2 million, again at 25p a pop – the par price. So is this an act of faith by Odey, or a case of if you owe the bank a million quid then it is the bank which has a problem?
AIM-listed Advanced Oncotherapy (AVO) is certainly keeping its Brokers – SI Capital and Allenby – busy. Only in April the company raised £1.7 million, although the funds weren’t in the bank when the announcement went out. In March the company rattled the tin for £2 million – plus an additional loan of another £1.5 million. Now it has rattled the tin once again – to raise just £800,000 (before expenses) as the company strains to keep its head above water.
AIM-listed Advanced Oncotherapy (AVO) has updated the market this morning on progress towards its first fully operational LIGHT system. The news is, for a change, good in that there is no further slippage. But will that last?
On 12th April 2022 AIM-listed Advanced Oncotherapy (AVO) announced an equity fundraise of £1.735 million at 25p a pop – a premium to market, but only at par price. We were told that the fundraise has been conducted through a direct subscription with the Company (the "Subscription") for a total of 6,940,000 new ordinary shares. So the money was in the bank, right? Wrong….
AIM-listed Advanced Oncotherapy (AVO) finally announced the fundraise that was obviously coming yesterday – at 25p, the nominal price (and the lowest price allowed by law). But the funding round is inadequate and the company will have to return to rattle the tin once again in a couple of months’ time.
I noted at the beginning of this month that AIM-listed Advanced Oncotherapy (AVO) needs to get a fundraise away pronto, but that its shares were threatening to drop below the nominal price of 25p, below which it cannot issue new shares by law. On Friday the shares closed at 24p (mid) and I would suggest that Advanced – or, rather, its shareholders – have a big problem.
AIM-listed and surely sort of cash Advanced Oncotherapy (AVO) announced yesterday morning that Prof Stephen Myers, executive director and the chairman of ADAM – Advanced’s development team in Geneva – had bought a total of 140,000 shares. At 27.64p (on average) that is £38,700 worth of stock. It sounds quite impressive, but this is certainly not a situation where it is advisable to follow director buying. In fact, I take the opposite view: the shares are a sell.
AIM-listed Advanced Oncotherapy (AVO) has announced that its first proton beam therapy unit at Daresbury has once again been delayed. First it was due in 2021, then the end of 2021, then Q1 2022….now we are told more tests during Q2 and then finalisation of the integration of the remaining high energy accelerating modules and reaching the 230MeV target over the summer. That sounds like Q3 for Mr Godot to finally make an appearance. Or not.
I see that shares in AIM-listed Advanced Oncotherapy (AVO) are down to just 26.5p – only a penny and a half above the nominal price. Normally that might not be an issue, but Advanced is a serial non-deliverer of promises and has had to place at regular intervals until now. So what chance a bucket-shop placing to keep the lights on whilst we await the ever-delayed first LIGHT system to even offer a sprinkling of hope for some revenue?
Well surprise, surprise! AIM-listed Advanced Oncotherapy (AVO) has announced that the first fully operational LIGHT system has been delayed from the end of this year to the end of Q1 next year. I noted HERE that the delay announced this morning was pretty well baked in. Given that we have moved from “could slip into Q1 2022” to “around the end of Q1 2022” in the space of less than two and a half months, it seems to me that further slippage is highly likely. Indeed, despite this morning’s announcement, one wonders whether any progress has been made at all since the announcement of diabolical interims at the end of September. So there will be at least another quarter sans revenue……what about the cash?
Oh dear, oh dear, oh dear. AIM-listed Advanced Oncotherapy has announced its interims to June: the numbers are predictably dreadful but the killer is surely the indication of a delay to the completion of the company’s first proton therapy LIGHT system.
AIM-listed Advanced Oncotherapy (AVO) announced yesterday, Friday 3rd September, that funds due in to settle the subscription announced back on 11th August would not be arriving in full for up to an additional two weeks. Yet on 31 August – just three days previously – the subscription shares were due to be issued on Friday. Hmm.
Back on August 17th I pointed out that according to AIM-listed Advanced Oncotherapy’s FY20 Annual Report, all the warrants exercisable at 25p issued back in July 2017 should have expired. Yet the night before, after-hours, the company had announced the exercise of 500,000 of those warrants. Last night the company slipped out an explanation at 6.14pm in its Result of GM announcement.
Here is an odd thing: last night, after hours at 4.48pm, AIM-listed Advanced Oncotherapy (AVO) announced that someone had issued an exercise notice in respect of 500,000 warrants issued back in July 2017 to subscribe for ordinary shares at 25p. Application to admit the shares has been made and admission is expected on or around August 20th. So what, you might ask. And that brings me to Advanced’s Annual Report for FY20.
